Ritter Pharmaceuticals, Inc. (RTTR) EPS Estimated At $-0.05; 5 Analysts Bullish Banco Bradesco S.A. (BBD)

February 15, 2018 - By Ellis Scott

Among 7 analysts covering Banco Bradesco SA (NYSE:BBD), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Banco Bradesco SA had 12 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was upgraded by Deutsche Bank on Monday, October 12 to “Buy”. The firm has “Buy” rating by Goldman Sachs given on Monday, September 11. The stock of Banco Bradesco S.A. (NYSE:BBD) has “Hold” rating given on Tuesday, March 22 by Deutsche Bank. The rating was downgraded by Citigroup to “Sell” on Friday, April 8. Citigroup upgraded the stock to “Buy” rating in Thursday, January 18 report. The stock of Banco Bradesco S.A. (NYSE:BBD) has “Buy” rating given on Monday, March 14 by Bank of America. J.P. Morgan upgraded the stock to “Buy” rating in Monday, January 22 report. Goldman Sachs maintained it with “Neutral” rating and $1.82 target in Monday, May 2 report. The stock of Banco Bradesco S.A. (NYSE:BBD) earned “Neutral” rating by Goldman Sachs on Wednesday, September 21. The company was upgraded on Wednesday, April 12 by Scotia Capital. See Banco Bradesco S.A. (NYSE:BBD) latest ratings:

22/01/2018 Broker: J.P. Morgan Rating: Buy New Target: $13.0 Upgrade
18/01/2018 Broker: Citigroup Rating: Buy Upgrade
11/09/2017 Broker: Goldman Sachs Rating: Buy New Target: $12.4 Upgrade




Analysts expect Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) to report $-0.05 EPS on February, 26.They anticipate $0.69 EPS change or 93.24% from last quarter’s $-0.74 EPS. After having $-0.14 EPS previously, Ritter Pharmaceuticals, Inc.’s analysts see -64.29% EPS growth. The stock increased 6.00% or $0.0181 during the last trading session, reaching $0.3199. About 153,109 shares traded. Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) has declined 56.21% since February 15, 2017 and is downtrending. It has underperformed by 72.91% the S&P500.

The stock increased 2.86% or $0.33 during the last trading session, reaching $11.86. About 15.48M shares traded or 77.02% up from the average. Banco Bradesco S.A. (NYSE:BBD) has risen 43.32% since February 15, 2017 and is uptrending. It has outperformed by 26.62% the S&P500.

Banco Bradesco S.A. provides banking and financial services and products to individuals, companies, and firms and institutions. The company has market cap of $73.76 billion. The firm operates in two divisions, Banking; and Insurance, Pension Plans and Capitalization Bond. It has a 16.22 P/E ratio. It accepts demand and time deposits, checking and savings accounts, interbank deposits from financial institutions, and accounts for salary purposes.

Among 5 analysts covering Ritter Pharmaceuticals (NASDAQ:RTTR), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Ritter Pharmaceuticals had 9 analyst reports since December 2, 2015 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Monday, October 23 report. The stock of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) has “Hold” rating given on Wednesday, July 5 by Maxim Group. The rating was initiated by Maxim Group on Thursday, April 14 with “Buy”. Roth Capital maintained it with “Buy” rating and $3.5000 target in Monday, June 5 report. Chardan Capital Markets initiated the stock with “Buy” rating in Wednesday, December 2 report. As per Wednesday, January 4, the company rating was initiated by Rodman & Renshaw. The stock of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) earned “Hold” rating by Maxim Group on Friday, August 4. Chardan Capital Markets maintained the stock with “Buy” rating in Tuesday, October 25 report.

Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The company has market cap of $15.84 million. The Company’s lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. It currently has negative earnings. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.